Author

Jitendra Kanodia

Xencor, Theravance Biopharma, Genentech Roche, Merrimack Pharmaceuticals, Princeton University - Cited by 785 - Clinical Pharmacology - Modeling and Simulation - Quantitative Systems Pharmacology - Pharmacokinetics and Pharmacodynamics - System

Biography

Dr. Jitendra Kanodia is currently working at Merrimack Pharmaceuticals, Princeton University. Author’s significant publications include “Role of HSGAGs in Regulation of FGF Signaling Pathway: Insights from Mathematical Modeling”. Author current research interests include Clinical Pharmacology, Signaling Pathways, Heparan Sulfate, Glycosaminoglycans.
Title
Cited by
Year
A microfluidic array for large-scale ordering and orientation of embryos
K Chung, Y Kim, JS Kanodia, E Gong, SY Shvartsman, H LuNature methods 8 (2), 171-176, 2011201
178
2011
Dynamics of the Dorsal morphogen gradient
JS Kanodia, R Rikhy, Y Kim, VK Lund, R DeLotto, J Lippincott-Schwartz, ...Proceedings of the National Academy of Sciences 106 (51), 21707-21712, 2009200
126
2009
Non-negative matrix factorization for detection and diagnosis of plantwide oscillations
AK Tangirala, J Kanodia, SL ShahIndustrial & engineering chemistry research 46 (3), 801-817, 2007200
69
2007
Pattern formation by graded and uniform signals in the early Drosophila embryo
JS Kanodia, HL Liang, Y Kim, B Lim, M Zhan, H Lu, CA Rushlow, ...Biophysical Journal 102 (3), 427-433, 2012201
56
2012
Feedback control of the EGFR signaling gradient: superposition of domain-splitting events in Drosophila oogenesis
JJ Zartman, JS Kanodia, LS Cheung, SY ShvartsmanDevelopment 136 (17), 2903-2911, 2009200
51
2009
Mathematical PKPD and safety model of bispecific TfR/BACE1 antibodies for the optimization of antibody uptake in brain
K Gadkar, DB Yadav, JY Zuchero, JA Couch, J Kanodia, MK Kenrick, ...European Journal of Pharmaceutics and Biopharmaceutics 101, 53-61, 2016201
42
2016
Deciphering the mechanism behind Fibroblast Growth Factor (FGF) induced biphasic signal-response profiles
J Kanodia, D Chai, J Vollmer, J Kim, A Raue, G Finn, B SchoeberlCell Communication and Signaling 12 (1), 1-18, 2014201
37
2014
Prospective Design of Anti‐Transferrin Receptor Bispecific Antibodies for Optimal Delivery into the Human Brain
JS Kanodia, K Gadkar, D Bumbaca, Y Zhang, RK Tong, W Luk, K Hoyte, ...CPT: pharmacometrics & systems pharmacology 5 (5), 283-291, 2016201
35
2016
A computational statistics approach for estimating the spatial range of morphogen gradients
JS Kanodia, Y Kim, R Tomer, Z Khan, K Chung, JD Storey, H Lu, PJ Keller, ...Development 138 (22), 4867-4874, 2011201
34
2011
Development of a therapeutic anti-HtrA1 antibody and the identification of DKK3 as a pharmacodynamic biomarker in geographic atrophy
I Tom, VC Pham, KJ Katschke Jr, W Li, WC Liang, J Gutierrez, A Ah Young, ...Proceedings of the National Academy of Sciences 117 (18), 9952-9963, 2020202
31
2020
Expression patterns of cadherin genes in Drosophila oogenesis
JJ Zartman, JS Kanodia, N Yakoby, X Schafer, C Watson, K Schlichting, ...Gene Expression Patterns 9 (1), 31-36, 2009200
26
2009
A compartmental model for the bicoid gradient
ME Kavousanakis, JS Kanodia, Y Kim, IG Kevrekidis, SY ShvartsmanDevelopmental biology 345 (1), 12-17, 2010201
24
2010
Evolution of BMP signaling in Drosophila oogenesis: a receptor-based mechanism
MG Niepielko, K Ip, JS Kanodia, DS Lun, N YakobyBiophysical Journal 102 (8), 1722-1730, 2012201
19
2012
ICH M9 guideline in development on biopharmaceutics classification system-based biowaivers: an industrial perspective from the IQ consortium
P Bransford, J Cook, M Gupta, S Haertter, H He, R Ju, J Kanodia, ...Molecular Pharmaceutics (2), 361-372, 2019201
17
2019
Safety and efficacy of ampreloxetine in symptomatic neurogenic orthostatic hypotension: a phase 2 trial
H Kaufmann, R Vickery, W Wang, J Kanodia, CA Shibao, ...Clinical Autonomic Research 31, 699-711, 2021202
10
2021
Transforming translation through quantitative pharmacology for high‐impact decision making in drug discovery and development
N Gupta, D Bottino, USH Simonsson, CJ Musante, T Bueters, TR Rieger, ...Clinical Pharmacology & Therapeutics 107 (6), 125-129, 2020202
8
2020
Pharmacokinetics and pharmacodynamics of ampreloxetine, a novel, selective norepinephrine reuptake inhibitor, in symptomatic neurogenic orthostatic hypotension
A Lo, L Norcliffe-Kaufmann, R Vickery, D Bourdet, J KanodiaClinical Autonomic Research 31, 39-403, 2021202
5
2021
Pharmacokinetics of ampreloxetine, a norepinephrine reuptake inhibitor, in healthy subjects and adults with attention-deficit/hyperactive disorder or fibromyalgia pain
J Kanodia, A Lo, RM Baldwin, RA Graham, DL BourdetClinical Pharmacokinetics 60, 121-11, 2021202
3
2021
Role of HSGAGs in regulation of fgf signaling pathway: insights from mathematical modeling
J Kanodia, G FinnJ Glycobiol 4 (11), 2, 2014201
3
2014
Use of pk/pd knowledge in guiding bispecific biologics research and development
A Baumann, S Prabhu, J KanodiaPharmaceutical Sciences Encyclopedia: Drug Discovery, Development, and …, 2010201
3
2010

Referred From: https://scholar.google.com/citations?user=fraVJnYAAAAJ&hl=en

Cited by
Citations 785
h-index 14
i10-index 15
Recommended Journals
Open Access Journals